Guobang Pharma Yönetim

Yönetim kriter kontrolleri 1/4

We currently do not have sufficient information about the CEO.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	5.1yrs

Son yönetim güncellemeleri

Recent updates

Calculating The Fair Value Of Guobang Pharma Ltd. (SHSE:605507)

Aug 26

These 4 Measures Indicate That Guobang Pharma (SHSE:605507) Is Using Debt Extensively

Jul 24

Guobang Pharma Ltd. (SHSE:605507) Analysts Just Cut Their EPS Forecasts Substantially

May 21

Fewer Investors Than Expected Jumping On Guobang Pharma Ltd. (SHSE:605507)

Apr 18

We Think Guobang Pharma (SHSE:605507) Is Taking Some Risk With Its Debt

Mar 25

CEO

Guobang Pharma CEO'su yok ya da onlar hakkında elimizde veri yok.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yuda Gong	CFO, Financial Director	5.1yrs	CN¥1.55m	0.90% CN¥ 96.7m
Jiajun Qiu	Chairman of the Board	5.1yrs	CN¥2.13m	9.92% CN¥ 1.1b
Yaqing Zhu	Director	5.1yrs	CN¥1.55m	1.35% CN¥ 145.0m
Zhongjian Meng	Supervisory Board Chairman	5.1yrs	Veri yok	0.31% CN¥ 33.9m
Xiaoming Wu	Independent Director	5.1yrs	CN¥140.00k	Veri yok
Sheng Jie Zhang	Independent Director	5.1yrs	CN¥140.00k	Veri yok

5.1yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 605507's board of directors are considered experienced (5.1 years average tenure).

Guobang Pharma Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Guobang Pharma Ltd., Annual General Meeting, May 08, 2024

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.31 (vs CN¥0.24 in 3Q 2023)

Guobang Pharma Ltd. to Report Q3, 2024 Results on Oct 19, 2024

Investor sentiment improves as stock rises 18%

Consensus EPS estimates increase by 13%

Price target increased by 8.3% to CN¥26.00

Second quarter 2024 earnings released: EPS: CN¥0.37 (vs CN¥0.29 in 2Q 2023)

Calculating The Fair Value Of Guobang Pharma Ltd. (SHSE:605507)

These 4 Measures Indicate That Guobang Pharma (SHSE:605507) Is Using Debt Extensively

Guobang Pharma Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Guobang Pharma Ltd. (SHSE:605507) Analysts Just Cut Their EPS Forecasts Substantially

Fewer Investors Than Expected Jumping On Guobang Pharma Ltd. (SHSE:605507)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Guobang Pharma Ltd., Annual General Meeting, May 08, 2024

Guobang Pharma Ltd. to Report Q1, 2024 Results on Apr 16, 2024

We Think Guobang Pharma (SHSE:605507) Is Taking Some Risk With Its Debt

Investor sentiment improves as stock rises 17%

Guobang Pharma Ltd. (SHSE:605507) announces an Equity Buyback for CNY 200 million worth of its shares.

Guobang Pharma Ltd. to Report Fiscal Year 2023 Results on Apr 16, 2024

Third quarter 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.40 in 3Q 2022)

Guobang Pharma Ltd. to Report Q3, 2023 Results on Oct 19, 2023

Second quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.53 in 2Q 2022)

Guobang Pharma Ltd. to Report First Half, 2023 Results on Jul 29, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.27 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.53 (vs CN¥0.41 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.36 (vs CN¥0.33 in 1Q 2021)

Full year 2021 earnings released: EPS: CN¥1.38 (vs CN¥1.71 in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

CEO

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş